Jakob Werner Hansen: Nordic VEX AZA Trial Reaches an Important Milestone
Jakob Werner Hansen, PhD at Rigshospitalet, shared a post on LinkedIn:
“We have reached an important milestone!
The last patient has now been included in our Nordic VEX AZA trial, where we are investigating azacitidine as a treatment for patients with VEXAS syndrome. The first prospective trial in the world to explore this.
We will present our pre-planned interim analysis in the near future, followed by the full analysis in 2027, when the last patient has been evaluated for the primary endpoint: reduction in UBA1 variant allele frequency.
The study is a truly pan Nordic collaboration, involving centres across Finland, Sweden, Norway, and Denmark with patients included from all four countries. It has been an incredible collaborative effort!
A huge thank you to all the patients participating in the trial, and to all the participating centres, physicians, nurses, monitors, and laboratory teams who have contributed to making this study possible.
Our trial office is small but truly amazing Markus Korsholm Kristensen and Sune Bengtsen Holm Hansen!
The next arm of the study is opening this week!
Thank you to the Danish Cancer Society (Kræftens Bekæmpelse) and the Novo Nordisk Foundation for supporting and enabling this study.
I have many lovely collaborators to thank, without the support it had never been possible money are small in investigator initiated trials but good people makes it possible.
P.S Our Nordic logo was created by the very first patient I enrolled in our trial a personal touch.
RigshospitaletNovo Nordisk FoundationKræftens Bekæmpelse (Danish Cancer Society)
Next stop 3rd international VEXAS workshop.”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience